Search Result

Results for "

Radioligand

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (5) Adenosine Receptor (1) Adrenergic Receptor (11) Amyloid-β (2) Biochemical Assay Reagents (1) Cannabinoid Receptor (2) Cholecystokinin Receptor (1) Cholinesterase (ChE) (3) CXCR (1) Dopamine Receptor (1) Drug-Linker Conjugates for ADC (1) GlyT (1) Histamine Receptor (1) iGluR (1) Integrin (1) Isotope-Labeled Compounds (6) Lipocalin Family (1) LPL Receptor (3) LRRK2 (1) mAChR (2) mGluR (1) Neurokinin Receptor (1) Neuropeptide Y Receptor (2) Orexin Receptor (OX Receptor) (1) Prostaglandin Receptor (1) PSMA (2) Radionuclide-Drug Conjugates (RDCs) (3) Serotonin Transporter (1) Sigma Receptor (2) Sodium Channel (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (9) Endocrinology (1) Infection (2) Inflammation/Immunology (2) Metabolic Disease (5) Neurological Disease (26)

By Targets:

5-HT Receptor (5)

Adenosine Receptor (1)

Adrenergic Receptor (11)

Amyloid-β (2)

Biochemical Assay Reagents (1)

Cannabinoid Receptor (2)

Cholecystokinin Receptor (1)

Cholinesterase (ChE) (3)

CXCR (1)

Dopamine Receptor (1)

Drug-Linker Conjugates for ADC (1)

GlyT (1)

Histamine Receptor (1)

iGluR (1)

Integrin (1)

Isotope-Labeled Compounds (6)

Lipocalin Family (1)

LPL Receptor (3)

LRRK2 (1)

mAChR (2)

mGluR (1)

Neurokinin Receptor (1)

Neuropeptide Y Receptor (2)

Orexin Receptor (OX Receptor) (1)

Prostaglandin Receptor (1)

PSMA (2)

Radionuclide-Drug Conjugates (RDCs) (3)

Serotonin Transporter (1)

Sigma Receptor (2)

Sodium Channel (1)

By Research Areas:

Cancer (8)

Cardiovascular Disease (9)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (2)

Metabolic Disease (5)

Neurological Disease (26)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113938

AZD4694 NAV4694	Amyloid-β	Cardiovascular Disease
AZD4694 (NAV4694), a fluorinated β-amyloid (Aβ) plaque neuroimaging PET radioligand, shows high affinity for Aβ fibrils (K_d = 2.3 nM) .

HY-100346

PK14105	Others	Others
PK14105 is a biological evaluation as a potential radioligand for PET studies of PBBS receptors.

HY-108972

SQ 29548	Prostaglandin Receptor	Metabolic Disease
SQ 29548, a high affinity radioligand, is a selective thromboxane-prostanoid (TP) receptor antagonist .

HY-156124

*Sigma-2 Radioligand* 1**	Sigma Receptor	Cancer
Sigma-2 Radioligand 1 (compound 1) is a Sigma-2 selective ligand. Sigma-2 Radioligand 1 has good biodistribution in mice and good in vivo activity in rats. [18F] Modified Sigma-2 Radioligand 1 for visualization of tumors in micro-PET/CT imaging, exhibiting high tumor uptake and tumor-to-background ratio. Experiments show that Sigma-2 Radioligand 1 binds highly specifically in U87MG glioma xenografts .

HY-149210

*S1PR1 Radioligand* 1**	LPL Receptor	Others
S1PR1 Radioligand 1(compound 6 h) is a specific S1PR1 radioligand with IC₅₀ = 8.7 nM. S1PR1 Radioligand 1 has good brain uptake and can be used as a S1PR1-specific F-18 radiotracer for studying the function of S1PR1 in brain diseases .

HY-155741

*CB2 PET Radioligand* 1**	Cannabinoid Receptor	Neurological Disease
CB2 PET Radioligand 1 (compound [18F]9) is a PET Radioligand targeting to hCB2 (Ki=7.7 nM). CB2 PET Radioligand 1 is prepared with Cu-mediated 18F-fluorination. CB2 PET Radioligand 1 shows high brain uptake in a murine model of neuroinflammation .

HY-169185

*Sigma-2 Radioligand* 2**	Sigma Receptor	Cancer
Sigma-2 Radioligand 2 (compund 4) exhibits low nanomolar affinity (Ki(σ2)=2.30 nM) and high subtype selectivity (Ki(σ1)/Ki(σ2) > 1500) for the σ2 receptor .

HY-P10220

NOTA-COG1410	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography .

HY-167898

MeS-IMPY	Amyloid-β	Neurological Disease
MeS-IMPY showed a high binding affinity to β-amyloid plaques extracted from Alzheimer's disease (AD) human brains or AD brain homogenates compared to IMPY (K_i=7.93 and 8.95 nM, respectively). [ ¹¹C]MeS-IMPY is a potential radioligand for imaging β-amyloid plaques with positron emission tomography (PET) .

HY-158266

DOTA-PSMA-EB-01 LNC1003	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC₅₀= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of ¹⁷⁷Lu in tumors .

HY-141804

ER176	Others	Neurological Disease
ER176 is a next generation PET radioligand for imaging 18 kDa translocator protein (TSPO), a biomarker for neuroinflammation .

HY-136873

UCB-J	Others	Others
UCB-J is a positron emission tomography (PET) radioligand for the synaptic vesicle protein 2A (SV2A) .

HY-141536

PSMA-ALB-56	Drug-Linker Conjugates for ADC	Cancer
PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder .

HY-163831

AZ12559322	mGluR	Neurological Disease
AZ12559322 is a positive allosteric modulator of mGluR2, with the K_i value of 1.31 nM. AZ12559322 can be used in neurological research .

HY-14121

MRS 1754 3 Publications Verification	Adenosine Receptor	Metabolic Disease Inflammation/Immunology
MRS 1754 is a selective antagonist radioligand for A_2B adenosine receptor with very low affinity for A₁ and A₃ receptors of both humans and rats .

HY-B1486

Oxprenolol hydrochloride 1 Publications Verification Ba 39089	Adrenergic Receptor	Cardiovascular Disease
Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a K_i of 7.10 nM in a radioligand binding assay using rat heart muscle .

HY-B1486A

Oxprenolol Ba 39089 free base	Adrenergic Receptor	Cardiovascular Disease
Oxprenolol (Ba 39089 free base) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a K_i of 7.10 nM in a radioligand binding assay using rat heart muscle .

HY-153432

TRV-7019	Cholinesterase (ChE)	Neurological Disease Cancer
TRV-7019 is a BBB-penetrable radioligand for brain imaging that target butyrylcholinesterase. TRV-7019 can be used for the diagnosis of an amyloid disease, multiple sclerosis, a brain tumor, or butyrylcholinesterase activity .

HY-103326

NIDA-41020	Cannabinoid Receptor	Neurological Disease
NIDA-41020 is a potent and selective cannabinoid receptor 1(CB1) antagonist with a K_i of 4.1 nM. NIDA-41020 was designed as a potential radioligand for use in positron emission tomography (PET) .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-110223

Atomoxetine-d3 hydrochloride	Adrenergic Receptor	Neurological Disease
Atomoxetine-d3 hydrochloride is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (K_i values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-149869

PSMA-IN-3	PSMA	Cancer
PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC₅₀ value of 13 nM. PSMA-IN-3 is suitable for developing an ¹⁸F-labeled radioligand for PET imaging of PSMA in prostate cancer .

HY-17385S

Atomoxetine-d5 hydrochloride Tomoxetine-d₅ hydrochloride; LY 139603-d₅; (R)-Tomoxetine-d5 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor	Neurological Disease
Atomoxetine-d₅ (hydrochloride) is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively)[1][2].

HY-118836

GSK215083	5-HT Receptor	Others
GSK215083 is a high affinity 5-HT6 receptor antagonist. GSK215083 can serves as a promising 5-HT6 radioligand candidate by radiolabeled with (11)C via methylation .

HY-103139

Altanserin hydrochloride	Others	Metabolic Disease
Altanserin is a 5-hydroxytryptamine (5-HT_2A) selective radioligand. Altanserin delivers human serotonin. Altanserin can be used to study the biochemical and cellular mechanisms of vulnerability to extracellular 5-HT increase .

HY-B1486S

Oxprenolol-d7 hydrochloride Ba 39089-d₇	Adrenergic Receptor	Cardiovascular Disease
Oxprenolol-d₇ (hydrochloride) is the deuterium labeled Oxprenolol hydrochloride. Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-B1486AS

Oxprenolol-d7	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease
Oxprenolol-d₇ is the deuterium labeled Oxprenolol. Oxprenolol (Ba 39089 free base) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-B1486R

Oxprenolol (hydrochloride) (Standard)	Adrenergic Receptor	Cardiovascular Disease
Oxprenolol (hydrochloride) (Standard) is the analytical standard of Oxprenolol (hydrochloride). This product is intended for research and analytical applications. Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle .

HY-103141

SB-258585 hydrochloride	Others	Neurological Disease
SB-258585 is a high affinity ligand for the 5-HT₆ receptor. SB-258585 binds highly to a single receptor population in a human cell line that recombines 5-HT₆ receptors. SB-258585 can be used to label recombinant and natural 5-HT₆ receptor .

HY-107370AS

(Rac)-Atomoxetine-d7 hydrochloride (Rac)-Tomoxetine d₇ (hydrochloride); (Rac)-LY 139603 d₇	Serotonin Transporter Sodium Channel Isotope-Labeled Compounds	Neurological Disease
(Rac)-Atomoxetine-d₇ (hydrochloride) is a deuterium labeled (Rac)-Atomoxetine hydrochloride. (Rac)-Atomoxetine hydrochloride is a racemic form of Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively)[1].

HY-148353

PF-06455943	LRRK2	Neurological Disease
PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC₅₀ value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) .

HY-P1096

A71623	Cholecystokinin Receptor	Metabolic Disease
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC₅₀s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .

HY-118424

JNJ-55511118	iGluR	Neurological Disease
JNJ-55511118 is a highly potent, reversible, and selective AMPA receptor inhibitor selective for TARP-γ8. JNJ-55511118 fully displaces the radioligand (20 nM) with the K_i of 26 nM in competition binding experiments. JNJ-55511118 is a tool molecule with potential therapeutic utility as an anticonvulsant or neuroprotectant .

HY-161246

uPSEM792	Others	Neurological Disease
uPSEM792 is a pharmacologically selective effector molecules (PSEM) agonist for PSAM ⁴-GlyR, with an affinity of K_i of 0.7 nM. uPSEM792 is a substrate for efflux transporters in brains of wild type and dual P-gp and BCRP knockout mice. uPSEM7952 is a possible lead for developing the PET radioligand for PSAM ⁴-GlyR .

HY-120792

DAU 5884	Others	Others
DAU 5884 is a muscarinic receptor antagonist with activity that discriminates between different muscarinic receptor subtypes. DAU 5884 discriminates between M4 and M2 receptor sites and is a highly potent M1-selective antagonist with specific activity at different muscarinic receptors characterized by radioligand binding studies and functional assays.

HY-133116

4-Hydroxyatomoxetine	Adrenergic Receptor	Neurological Disease
4-Hydroxyatomoxetine is an active metabolite of Atomoxetine. 4-Hydroxyatomoxetine is metabolized by the enzyme cytochrome P450 2D6 (CYP2D6). Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (K_i values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively) .

HY-147366

*RBP4 ligand-1*	Lipocalin Family	Metabolic Disease
RBP4 ligand-1 is a non-retinoid ligands for (RBP4) retinol-binding protein 4. The hRBP4_SPA IC₅₀ and RBP4–TTR FRET IC₅₀ values are 0.23±0.11 and 0.13±0.12 μM in the radioligand binding assay and FRET assay, respectively .

HY-122203A

PCS1055	mAChR Cholinesterase (ChE)	Neurological Disease
PCS1055 is a selective and competitive antagonist for muscarinic M4 receptor with an IC₅₀ of 18.1 nM and a K_d of 5.72 nM. PCS1055 inhibits radioligand [ ³H]-NMS binding to the M4 receptor with a K_i of 6.5 nM. PCS1055 is also an inhibitor for AChE with IC₅₀ of 22 nM and 120 nM for electric eel and human AChE, respectively .

HY-N8295

Leucomycin A13 Kitasamycin A13	Others	Infection
Leucomycin A13 is a macrolide antibiotic and a component of the leucomycin complex originally isolated from S. kitasatoensis. It is active against B. subtilis, S. aureus, M. luteus, and E. coli with MIC values of 0.16, 0.16, 0.08 and >10 μg/mL, respectively. It binds to ribosomes with an IC₅₀ value of 1.2 μM in a radioligand binding assay.

HY-111189

GSK931145	GlyT	Neurological Disease
GSK931145 is a glycine transporter 1 (GlyT1) inhibitor with anti-epileptic activity. GSK931145 exhibits a low minimum effective dose in the maximum electrical stimulation threshold test, indicating that it has a significant anti-epileptic effect. GSK931145 is also suitable as a positron emission tomography (PET) radioligand for quantifying the availability of glycine transporters in the living brain .

HY-122537A

Arotinolol	Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease
Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand ¹²⁵I-ICYP to 5HT_1B-serotonergic receptor sites . Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .

HY-122537

Arotinolol hydrochloride	Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease
Arotinolol hydrochloride is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol hydrochloride also shows potency for inhibiting the binding of the radioligand ¹²⁵I-ICYP to 5HT_1B-serotonergic receptor sites . Arotinolol hydrochloride is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .

HY-116020

FAUC 365	Dopamine Receptor	Neurological Disease
FAUC 365 is a highly dopamine D3 receptor-selective antagonist with K_i values of 0.5 nM, 340, 2600, and 3600 nM at D3, D4.4, D2_short, and D2_Long receptors, respectively. FAUC 365 can be used for the research of schizophrenia, and Parkinson's disease .

HY-10569

Ponesimod 2 Publications Verification ACT-128800	LPL Receptor	Inflammation/Immunology
Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

HY-126402

Arg-Gly-Asp TFA	Integrin	Cancer
Arg-Gly-Asp (RGD) is a synthetic peptide corresponding to the cell adhesion sequence for the integrins αVβ1, αVβ3, αVβ5, αVβ6, αVβ8, α8β1, and α5β1. It is a component of radioligands and peptidomimetics that have been used in the study of integrin expression and activity in vivo.

HY-103151

CP94253 hydrochloride	5-HT Receptor	Neurological Disease
CP94253 hydrochloride is a potent and selective agonist of 5-HT_1B receptor (K_i= 2 nM in a radioligand binding assay).K_i values for 5-HT_1A, 5-HT_1D, 5-HT_1C and 5-HT₂ receptors are 89, 49, 860, and 1600 nM respectively . CP94253 hydrochloride is centrally active upon systemic administration in vivo .

HY-W653969

Arotinolol-d5 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor 5-HT Receptor	Cardiovascular Disease
Arotinolol-d₅ (hydrochloride) is deuterium labeled Arotinolol. Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand ¹²⁵I-ICYP to 5HT_1B-serotonergic receptor sites. Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .

HY-119005A

YM-49598 iodide	Neurokinin Receptor	Neurological Disease
YM-49598 iodide is a tachykinin NK-1 receptor antagonist. YM-49598 iodide can inhibit drug-induced bladder contraction in rats, with IC₅₀ of 11 μg/kg .

HY-P10444

DOTA Conjugated JM#21 derivative 7	CXCR Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney .

Cat. No.	Product Name	Type

HY-D2343

PB0822	Dyes
PB0822 can be used for in vivo PET imaging when labeled with [ ¹⁸F]fluoride. [ ¹⁸F]PB0822 is a PET radioligand. [ ¹⁸F]PB0822 has a cLogP value of 1.54, which is a good predictive index for BBB penetration. [ ¹⁸F]PB0822 can be used for Alzheimer’s Disease research .

Cat. No.	Product Name	Target	Research Area

HY-P1096

A71623	Cholecystokinin Receptor	Metabolic Disease
A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC₅₀s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .

HY-P10220

NOTA-COG1410	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs)	Others
NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography .

HY-158266

DOTA-PSMA-EB-01 LNC1003	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC₅₀= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of ¹⁷⁷Lu in tumors .

HY-P1321

GR231118 1229U91; GW1229	Neuropeptide Y Receptor	Neurological Disease
GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pK_i= 8.8) .

HY-P1321A

GR231118 TFA 1229U91 TFA; GW1229 TFA	Neuropeptide Y Receptor	Neurological Disease
GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pK_i of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC₅₀=8.6; pK_i=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pK_i= 8.8) .

HY-P10444

DOTA Conjugated JM#21 derivative 7	CXCR Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney .

Cat. No.	Product Name	Chemical Structure

HY-B1486S

Oxprenolol-d7 hydrochloride
Oxprenolol-d₇ (hydrochloride) is the deuterium labeled Oxprenolol hydrochloride. Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-10569S1

Ponesimod-d7

Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation .

HY-17385S

Atomoxetine-d5 hydrochloride
Atomoxetine-d₅ (hydrochloride) is the deuterium labeled Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively)[1][2].

HY-B1486AS

Oxprenolol-d7
Oxprenolol-d₇ is the deuterium labeled Oxprenolol. Oxprenolol (Ba 39089 free base) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-107370AS

(Rac)-Atomoxetine-d7 hydrochloride
(Rac)-Atomoxetine-d₇ (hydrochloride) is a deuterium labeled (Rac)-Atomoxetine hydrochloride. (Rac)-Atomoxetine hydrochloride is a racemic form of Atomoxetine hydrochloride. Atomoxetine hydrochloride is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5 nM, 77 nM and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively)[1].

HY-W653969

Arotinolol-d5 hydrochloride

Arotinolol-d₅ (hydrochloride) is deuterium labeled Arotinolol. Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker . Arotinolol also shows potency for inhibiting the binding of the radioligand ¹²⁵I-ICYP to 5HT_1B-serotonergic receptor sites. Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases .

HY-10569S

Ponesimod-d4
Ponesimod-d₄ (ACT-128800-d₄)is the deuterium labeledPonesimod(HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: